期刊文献+

响应面法优化重组大肠杆菌产ADI酶发酵培养基 被引量:3

Fermentation Medium Optimization for Arginine Deiminase Production from Recombinant Escherichia coli by Response Surface Methodology
下载PDF
导出
摘要 在单因素优化的基础上,采用响应面分析方法对重组大肠杆菌生产精氨酸脱亚胺酶(ADI)的发酵培养基进行了优化。借助于SAS软件,结合Plackett-Burman和Box-Behnken实验设计对5种培养基组分进行优化。结果表明,最佳培养基组分为胰蛋白胨11.16 g/L,酵母提取物20 g/L,甘油6.3 g/L,磷酸氢二钾16.38 g/L,磷酸二氢钾2.31 g/L。采用优化后的培养基进行摇瓶发酵,ADI酶活达到5.7 U/m L发酵液,比初始培养基(3.72 U/m L发酵液)提高了1.53倍,比LB培养基(2.83 U/m L发酵液)提高了2.01倍。采用优化后的培养基在3 L发酵罐中进行发酵,ADI酶活达到15.17 U/m L发酵液,较LB培养基(4.32 U/m L发酵液)提高了3.51倍。 Response surface methodology was used to optimize the fermentation medium of recombinant E. coli for arginine deiminase production on the basis of single factor optimization. Five medium factors were optimized by SAS software combined with Plackett-Burman and Box-Behnken design. The optimized fermentation medium contains 11.16 g/L tryptone, 20 g/L yeast extract, 6.3 g/L glycerol, 16.38 g/L K2HPO4,and 2.31 g/L KH2PO4. Using the optimized medium,the activity of ADI reached 5.7 U/mL broth,which was 1.53-fold higher than that of in the initial medium (3.72 U/mL)and 2.01-fold of that in LB medium (2.83 U/mL). In a 3-L bioreactor,ADI activity of 15.17 U/mL broth was attained using optimized medium, which was remarkably enhanced compared with that of LB medium (4.32 U/mL).
出处 《食品与生物技术学报》 CAS CSCD 北大核心 2015年第5期475-481,共7页 Journal of Food Science and Biotechnology
基金 国家自然科学基金项目(30900030 21276112) 国家973计划项目(2011CB710800) 教育部新世纪优秀人才支持计划项目(NCET-11-0658)
关键词 大肠杆菌 培养基优化 ADI酶活 响应面 Escherichia coli, medium optimization, arginine deiminase, response surface
  • 相关文献

参考文献25

  • 1Izzo F,Marra P,Beneduce G,et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma : results from phase I/II studies[J]. Journal of Clinical Oncology, 2004,22 ( 10 ) : 1815-1822.
  • 2Whang-Peng J, Cheng A L, Hsu C, et al. Clinical development and future direction for the treatment of hepatocellular carcinoma [J]. Journal of Experimental & Clinical Medicine, 2010,2 (3) : 93-103.
  • 3Ni Y, Schwaneberg U, Sun Z. Arginine deiminase, a potential anti-tumor drug[J]. Cancer Letters, 2008,261 ( 1 ) : 1-11.
  • 4Ensor C M,Holtsberg F W,Bomalaski J S,et al. Pegylated arginine deiminase (ADI-SS-PEG20,000 mw)inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo[J]. Cancer Research, 2002,62 ( 19 ) :5443-5450.
  • 5Takaku H,Matsumoto M,Misawa S,et al. Anti-tumor activity of arginine deiminase from Mycoplasma arginini and its growth-inhibitory mechanism[J]. Jpn J Cancer Res, 1995,86 (9) : 840-846.
  • 6Glazer E S,Piccirillo M,Albino V,et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatoeeUular carcinoma[J]. Journal of Clinical Oncology, 2010,28 ( 13 ) : 2220-2226.
  • 7Shen L J,Shen W C. Drug evaluation:AD1-PEG-20--a PEGylated arginine deiminase for arginine-auxotrophic cancers [J]. Current Opinion in Molecular Therapeutics, 2006,8 (3) : 240-248.
  • 8Liu Y,Sun Z.Ni Y,et al. Isolation and identification of an arginine deiminase producing strain Pseudomonos plecoglossicido CGMCC2039[J]. World Journal of Microbiology and Biotecbnology, 2008,24 ( 10 ) : 2213-2219.
  • 9Ascierto P A, Scala S, Castello G, et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma:results from phase I and I1 studies[J]. Journal of Clinical Oncology, 2005,23 (30) : 7660-7668.
  • 10Gong H ,Zolzer F,Von Recklinghausen G ,et al. Arginine deiminase inhibits proliferation of human leukemia ceils more potently than asparaginase by inducing cell cycle arrest and apoptosis[J]. Leukemia, 2000,14 (5) :826-829.

二级参考文献32

共引文献203

同被引文献35

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部